An exploratory study of nivolumab (nivo) with or without ipilimumab (ipi) according to the percentage of tumoral CD8 cells in advanced metastatic cancer

MLA

James P. Allison, et al. “An Exploratory Study of Nivolumab (Nivo) with or without Ipilimumab (Ipi) According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer.” Journal of Clinical Oncology, vol. 39, May 2021, p. 2573. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........365a3b695b1aa71f0e96c28069f44dd7&authtype=sso&custid=ns315887.

APA

James P. Allison, Cheryl Selinsky, Nicholas L. Bayless, Jill O’Donnell-Tormey, Ute Dugan, Apostolia Maria Tsimberidou, Padmanee Sharma, F. Stephen Hodi, Marko Spasic, Michael Tezlaff, Shivaani Kummar, Leo Nissola, Alexandra Drakaki, David Y. Oh, Lacey J. Kitch, Jennifer C Ayran, Christopher R. Cabanski, Vanessa M. Hubbard-Lucey, Theresa LaVallee, & Danny N. Khalil. (2021). An exploratory study of nivolumab (nivo) with or without ipilimumab (ipi) according to the percentage of tumoral CD8 cells in advanced metastatic cancer. Journal of Clinical Oncology, 39, 2573.

Chicago

James P. Allison, Cheryl Selinsky, Nicholas L. Bayless, Jill O’Donnell-Tormey, Ute Dugan, Apostolia Maria Tsimberidou, Padmanee Sharma, et al. 2021. “An Exploratory Study of Nivolumab (Nivo) with or without Ipilimumab (Ipi) According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer.” Journal of Clinical Oncology 39 (May): 2573. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........365a3b695b1aa71f0e96c28069f44dd7&authtype=sso&custid=ns315887.